Lyra Therapeutics (LYRA) Cash from Restructuring (2024 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Cash from Restructuring of $207000.0 in Q4 2025, up 148.48% on a QoQ basis from -$427000.0 in Q3 2025, and up 140.75% YoY from $85982.0 in Q4 2024.
Lyra Therapeutics (LYRA) Cash from Restructuring (2024 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Cash from Restructuring for 2 consecutive years, with $207000.0 the latest figure, recorded in Q4 2025.
- Cash from Restructuring for Q4 2025 came in at $207000.0, up 140.75% year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.1 million (changed N/A YoY), and the FY2025 annual result was -$1.1 million, down 124.87% from the prior year.
- Cash from Restructuring for Q4 2025 stood at $207000.0, up from -$427000.0 in the prior quarter.
- The five-year high for Cash from Restructuring was $1.7 million in Q3 2024, with the low at -$553000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 207,000.00 |
| Sep 30, 2025 | -427,000.00 |
| Jun 30, 2025 | -553,000.00 |
| Mar 31, 2025 | -308,000.00 |
| Dec 31, 2024 | -508,000.00 |
| Sep 30, 2024 | 1.73 Mn |